A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. 1997

J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Naval Medical Center, Bethesda, Maryland 20889, USA. jgremj@helix.nih.gov

The combination of IFN-alpha-2a (IFN-alpha) and IFN-gamma-1b (IFN-gamma) has been found to produce more than additive cytotoxicity with fluorouracil (5-FU) in HT 29 colon cancer cells due to enhanced DNA-directed effects. We therefore studied the combination of IFN-gamma with IFN-alpha, 5-FU, and leucovorin (LV) in a clinical trial. Fifty-three patients received an initial cycle of 5 million units (MU)/m2 IFN-alpha s.c. on days 1-7 with 500 mg/m2 LV and 370 mg/m2 5-FU i.v. on days 2-6. IFN-gamma was then added once tolerable doses of 5-FU and IFN-alpha were established for each patient. IFN-gamma was administered at one of six dose levels between 0.3-4.8 MU/m2 s.c. on days 1-7. This design permitted comparison of the clinical toxicity and pharmacokinetics of 5-FU in two consecutive cycles in an individual treated with the same doses of 5-FU/LV/IFN-alpha in the absence and presence of IFN-gamma. In 43 matched patient cycles, the addition of IFN-gamma did not seem to worsen gastrointestinal toxicity, and skin toxicity tended to be milder. 5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04). In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032). Overall, 38% and 26% of patients had grade 3-4 diarrhea and mucositis. Dose reductions of IFN-gamma for chronic fatigue, malaise, or anorexia were ultimately required more frequently with >/=2.4 MU/m2 (P = 0.018), and the maximum tolerated dose of IFN-gamma was considered to be 1.2 MU/m2/ day. Objective responses were seen in 41% of 29 measurable colorectal cancer patients. Compared to our previous experience with 5-FU/LV/IFN-alpha, IFN-gamma and IFN-alpha appeared to have opposite effects on 5-FU clearance. These results suggest that any potential benefit of adding IFN-alpha to 5-FU/LV on this schedule may not depend solely on alterations in 5-FU clearance.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
January 1993, European journal of cancer (Oxford, England : 1990),
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
December 1992, Journal of the National Cancer Institute,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
August 1995, Cancer,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
September 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
January 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
February 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
January 1992, Cancer chemotherapy and pharmacology,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
January 1993, Acta oncologica (Stockholm, Sweden),
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
October 1994, British journal of cancer,
J L Grem, and N McAtee, and R F Murphy, and F M Balis, and E Cullen, and A P Chen, and J M Hamilton, and S M Steinberg, and M Quinn, and J M Sorensen, and S G Arbuck, and D Lawrence, and J Pang, and C J Allegra
October 1998, American journal of clinical oncology,
Copied contents to your clipboard!